BioArctic partner Eisai to present five-year lecanemab data at CTAD 2026

PUBT · 2d ago
BioArctic partner Eisai to present five-year lecanemab data at CTAD 2026
  • BioArctic partner Eisai will present new lecanemab data at the CTAD conference in Boston, November 16-19, 2026.
  • Five-year Clarity AD findings will address long-term treatment outcomes in early Alzheimer's disease.
  • Real-world LEADER analyses will examine treatment outcomes across diverse US clinical settings, including at-home subcutaneous administration.
  • Updated projections suggest continuous lecanemab treatment could delay progression to moderate disease.
  • A BioArctic poster will examine lecanemab's binding profile in patients with early Alzheimer's disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioArctic AB published the original content used to generate this news brief via Cision (Ref. ID: 202610300300BITN____UKPR__EN_20261030-BIT-2297-0) on October 30, 2026, and is solely responsible for the information contained therein.